; (2) primary data on ME/CFS natural history and symptom progress, including related data on the post-viral nature, risk factors, and various conditions known to be comorbid with ME/CFS; (3) the availability of medical and social services for individuals with ME/CFS and their families; and (4) the disaggregation of such data by population and geographical region. (c) Collaborative research centers In carrying out subsection (a), the Director of NIH shall award grants and contracts to public or nonprofit private entities to pay all or part of the cost of establishing or expanding collaborative research centers for ME/CFS, including the costs of stakeholder engagement and patient outreach programs. (d) Developing research agenda The Director of NIH, in coordination with the Director of the Institute, the Trans-NIH ME/CFS Working Group, interagency partners, stakeholders, and disease experts, shall develop a research agenda— (1) drawing from the September 2019 report of the National Advisory Neurological Disorders and Stroke Council Working Group for ME/CFS; and (2) prioritizing outcomes for COVID–19 patients exhibiting ME/CFS symptoms and survivors of COVID–19 with ME/CFS. (e) Research program In carrying out subsection (b), the Director of NIH, in coordination with the Director of the Institute and the directors of other national research institutes and centers, and utilizing the National Institutes of Health’s process of scientific peer review, shall— (1) prioritize opportunities that accelerate diagnosis and identify effective treatments for COVID–19 patients exhibiting ME/CFS symptoms and survivors of COVID–19 with ME/CFS; (2) prioritize projects with new and early career researchers; (3) expand ME/CFS research programs including the continuation of existing studies, remote convenings with stakeholders, and new ME/CFS disease specific funding announcements, including set-aside funds